The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers

British Journal of Clinical Pharmacology

Volumn 65, Issue 5, 2008, Pages 693-700

  Tateishi, Tomonori ^b   Miura, Masatomo ^c   Suzuki, Toshio ^c   Uno, Tsukasa ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c AKITA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Enantiomer; Fexofenadine; Itraconazole; P glycoprotein

Indexed keywords

FEXOFENADINE; ITRACONAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXCRETION; ENANTIOMER; FEMALE; HUMAN; JAPANESE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEREOCHEMISTRY;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HUMANS; ITRACONAZOLE; MALE; P-GLYCOPROTEIN; TERFENADINE;

EID: 42149159955     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03116.x     Document Type: Article

References (34)

1. Kim RB. Transporters and xenobiotic disposition. Toxicology 2002 181-182 : 291 7.
2. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003 42 : 59 98.
3. Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 2003 33 : 6 9.
4. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999 27 : 866 71.
5. Putnam WS, Ramanathan S, Pan L, Takahashi LH, Benet LZ. Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. J Pharm Sci 2002 91 : 2622 35.
6. Perloff MD, von Moltke LL, Greenblatt DJ. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J Clin Pharmacol 2002 42 : 1269 74.
7. Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000 59 : 301 21.
8. Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, Cha IJ, Shin JG. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther 2005 78 : 191 201.
9. Shimizu M, Uno T, Sugawara K, Tateishi T. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 2006 61 : 538 44.
10. Shimizu M, Uno T, Sugawara K, Tateishi T. Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 2006 62 : 372 6.
11. Uno T, Shimizu M, Sugawara K, Tateishi T. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. Drug Metab Dispos 2006 34 : 1875 9.
12. Hooiveld GJ, Heegsma J, van Montfoort JE, Jansen PL, Meijer DK, Muller M. Stereoselective transport of hydrophilic quaternary drugs by human MDR1 and rat Mdr1b P-glycoproteins. Br J Pharmacol 2002 135 : 1685 94.
13. Siccardi D, Kandalaft LE, Gumbleton M, McGuigan C. Stereoselective and concentration-dependent polarized epithelial permeability of a series of phosphoramidate triester prodrugs of d4T: an in vitro study in Caco-2 and Madin-Darby canine kidney cell monolayers. J Pharmacol Exp Ther 2003 307 : 1112 9.
14. Luurtsema G, Molthoff CF, Windhorst AD, Smit JW, Keizer H, Boellaard R, Lammertsma AA, Franssen EJ. (R)- and (S)- [11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl Med Biol 2003 30 : 747 51.
15. Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R) -[(11) C] verapamil and positron emission tomography. Clin Pharmacol Ther 2006 79 : 540 8.
16. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, Cascorbi I. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002 72 : 572 83.
17. Hollt V, Kouba M, Dietel M, Vogt G. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol 1992 43 : 2601 8.
18. Sandström R, Karlsson A, Lennernas H. The absence of stereo selective P-glycoprotein-mediated transport of R/S-verapamil across the rat jejunum. J Pharm Pharmacol 1998 50 : 729 35.
19. Zschiesche M, Lemma GL, Klebingat KJ, Franke G, Terhaag B, Hoffmann A, Gramatte T, Kroemer HK, Siegmund W. Stereoselective disposition of talinolol in man. J Pharm Sci 2002 91 : 303 11.
20. Robbins DK, Castles MA, Pack DJ, Bhargava VO, Weir SJ. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 1998 19 : 455 63.
21. Miura M, Uno T, Tateishi T, Suzuki T. Determination of fexofenadine enantiomers in human plasma with high-performance liquid chromatography. J Pharm Biomed Anal 2007 43 : 741 5.
22. Miura M, Uno T, Tateishi T, Suzuki T. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality 2007 19 : 223 7.
23. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002 71 : 11 20.
24. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 2004 308 : 438 45.
25. Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, Sugiyama Y. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 2005 33 : 1477 81.
26. Uno T, Shimizu M, Sugawara K, Tateishi T. Sensitive determination of itraconazole and its active metabolite in human plasma by column-switching hgh-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 2006 28 : 526 31.
27. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987 84 : 7735 8.
28. Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 2003 33 : 1 5.
29. Neuhoff S, Langguth P, Dressler C, Andersson TB, Regardh CG, Spahn-Langguth H. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites. Int J Clin Pharmacol Ther 2000 38 : 168 79.
30. Bernsdorf A, Giessmann T, Modess C, Wegner D, Igelbrink S, Hecker U, Haenisch S, Cascorbi I, Terhaag B, Siegmund W. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol 2006 61 : 440 50.
31. Szabo D, Molnar J. The role of stereoselectivity of chemosensitizers in the reversal of multidrug resistance of mouse lymphoma cells. Anticancer Res 1998 18 : 3039 44.
32. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001 69 : 114 21.
33. Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther 2006 79 : 218 30.
34. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007 81 : 362 70.